N
New Haven Pharmaceuticals
Welcome to New Haven Pharmaceuticals | New Haven Pharmaceuticals
About New Haven Pharmaceuticals
New Haven Pharmaceuticals is a specialty pharmaceutical company focused on developing proprietary prescription drugs. The company's strategy involves utilizing well-established compounds, including those designated as Generally Recognized as Safe (GRAS), in combination with its proprietary controlled-release technologies to create new pharmaceutical products.
One of the company's notable achievements is the development and FDA approval of Durlaza, an extended-release aspirin capsule. This product is indicated for the secondary prevention of stroke and other acute cardiac events, targeting patients with cardiovascular disease. By creating a controlled-release formulation of a widely used and well-known drug like aspirin, New Haven Pharmaceuticals aims to offer improved therapeutic options for patients.
The company operates in the competitive pharmaceutical market, with a business model centered on the research, development, and commercialization of its proprietary drug formulations. As a privately held entity, its financial success is tied to the market adoption and sales of its products like Durlaza, which are prescribed by healthcare professionals and distributed through pharmacies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 57.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Risk Management, Biotechnology, Cardiology and cardiovascular, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2C
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBT✓Debt | Aug 2016 | $600K | — | Undisclosed | — |
| DEBT✓Debt | Oct 2015 | $6.3M | — | Horizon Technology Finance Corporation | — |
Growth signals
Latest recorded traffic for New Haven Pharmaceuticals is 1.6K monthly website visits, up 190.9% over the last three months. New Haven Pharmaceuticals's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
SingulexLife Science Products and Cardiovascular Monitoring |
Alameda, United States | Operational | 3 | $137M | $200M |
CalcisconCalciscon's vision is to improve the cardiovascular risk management of kidney patients |
Biel/Bienne, Switzerland | Operational | |||
CroivalveTreating Heart Valve Disease |
Dublin, Ireland | Operational | |||
ANTERIOSInnovative biopharmaceutical solutions tackling the toughest health challenges with a focus on impactful treatments |
New York City, United States | Acquired | |||
ValbiotisSolutions for cardio-metabolic diseases prevention |
Perigny, France | Operational | |||
OMEICOS TherapeuticsPrevention and treatment of cardiovascular diseases |
Berlin, Germany | Operational | |||
SomaLogicUnlocking protein biomarkers to transform healthcare |
Boulder, United States | Acquired | |||
Signpath PharmaBiotechnology company developing therapeutics using curcuminoids extracted from the root of the curcuma longa plant |
Quakertown, United States | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
New Haven Pharmaceuticals in the North Haven ecosystem
The New Haven Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Kuzari Group
Connecticut Innovations- EFEJ Funds
Yale School of Management
Yale Law School
Series B and later2 investors entered at this stage
Advantage Capital
Horizon Technology Finance Corporation
Other known investors1 additional known investor
Yale University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about New Haven Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See New Haven Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










